{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T10:24:25Z","timestamp":1775471065969,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,1,22]],"date-time":"2009-01-22T00:00:00Z","timestamp":1232582400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2009,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The anticipated extent of antiviral use during an influenza pandemic can have adverse consequences for the development of drug resistance and rationing of limited stockpiles. The strategic use of drugs is therefore a major public health concern in planning for effective pandemic responses.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We employed a mathematical model that includes both sensitive and resistant strains of a virus with pandemic potential, and applies antiviral drugs for treatment of clinical infections. Using estimated parameters in the published literature, the model was simulated for various sizes of stockpiles to evaluate the outcome of different antiviral strategies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We demonstrated that the emergence of highly transmissible resistant strains has no significant impact on the use of available stockpiles if treatment is maintained at low levels or the reproduction number of the sensitive strain is sufficiently high. However, moderate to high treatment levels can result in a more rapid depletion of stockpiles, leading to run-out, by promoting wide-spread drug resistance. We applied an antiviral strategy that delays the onset of aggressive treatment for a certain amount of time after the onset of the outbreak. Our results show that if high treatment levels are enforced too early during the outbreak, a second wave of infections can potentially occur with a substantially larger magnitude. However, a timely implementation of wide-scale treatment can prevent resistance spread in the population, and minimize the final size of the pandemic.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Our results reveal that conservative treatment levels during the early stages of the outbreak, followed by a timely increase in the scale of drug-use, will offer an effective strategy to manage drug resistance in the population and avoid run-out. For a 1918-like strain, the findings suggest that pandemic plans should consider stockpiling antiviral drugs to cover at least 20% of the population.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2334-9-8","type":"journal-article","created":{"date-parts":[[2009,8,7]],"date-time":"2009-08-07T09:39:14Z","timestamp":1249637954000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Antiviral resistance during pandemic influenza: implications for stockpiling and drug use"],"prefix":"10.1186","volume":"9","author":[{"given":"Julien","family":"Arino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher S","family":"Bowman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed M","family":"Moghadas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,1,22]]},"reference":[{"issue":"3","key":"773_CR1","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1445-5994.2006.01036.x","volume":"36","author":"LC Jennings","year":"2006","unstructured":"Jennings LC, Peiris M: Avian influenza H5N1: is it a cause for concern?. Intern Med J. 2006, 36 (3): 145-147. 10.1111\/j.1445-5994.2006.01036.x.","journal-title":"Intern Med J"},{"key":"773_CR2","unstructured":"WHO. 2008, [http:\/\/www.who.int\/csr\/disease\/avian_influenza\/country\/cases_table_2008_06_19\/en\/index.html]"},{"key":"773_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/nature04017","volume":"437","author":"NM Ferguson","year":"2005","unstructured":"Ferguson NM, Cummings DAT, Cauchemez S, Fraser C, Riley S, Meeyai A, Iamsirithaworn S, Burke DS: Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature. 2005, 437: 209-214. 10.1038\/nature04017.","journal-title":"Nature"},{"key":"773_CR4","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/nature04795","volume":"442","author":"NM Ferguson","year":"2006","unstructured":"Ferguson NM, Cummings DAT, Fraser C, Cajka J, Cooley P, Burke D: Strategies for mitigating an influenza pandemic. Nature. 2006, 442: 448-452. 10.1038\/nature04795.","journal-title":"Nature"},{"issue":"9","key":"773_CR5","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.3201\/eid1209.041344","volume":"11","author":"R Gani","year":"2005","unstructured":"Gani R, Hughes H, Fleming D, Griffin T, Medlock J, Leach S: Potential impact of antiviral drug use during influenza pandemic. Emerg Infect Dis. 2005, 11 (9): 1355-1362.","journal-title":"Emerg Infect Dis"},{"key":"773_CR6","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1093\/aje\/kwh092","volume":"159","author":"IM Longini Jr","year":"2004","unstructured":"Longini IM, Halloran ME, Nizam A, Yang Y: Containing pandemic influenza with antiviral agents. Am J Epidemiol. 2004, 159: 623-633. 10.1093\/aje\/kwh092.","journal-title":"Am J Epidemiol"},{"key":"773_CR7","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1126\/science.1115717","volume":"309","author":"IM Longini Jr","year":"2005","unstructured":"Longini IM, Nizam A, Xu S, Ungchusak K, Hanshaoworakul W, Cummings DAT, Halloran ME: Containing pandemic influenza at the source. Science. 2005, 309: 1083-1087. 10.1126\/science.1115717.","journal-title":"Science"},{"key":"773_CR8","unstructured":"WHO checklist for influenza pandemic preparedness planning. 2005, [http:\/\/www.who.int\/csr\/resources\/publications\/influenza\/WHO_CDS_CSR_GIP_2005_4\/en\/]"},{"key":"773_CR9","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1001\/jama.284.13.1655","volume":"184","author":"CB Bridges","year":"2000","unstructured":"Bridges CB, Thompson WW, Meltzer MI, Reeve GR, Talamonti WJ, Cox NJ, Lilac HA, Hall H, Klimov A, Fukuda K: Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial. JAMA. 2000, 184: 1655-1663. 10.1001\/jama.284.13.1655.","journal-title":"JAMA"},{"key":"773_CR10","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1093\/jac\/dkl376","volume":"58","author":"J Democratis","year":"2006","unstructured":"Democratis J, Pareek M, Stephenson I: Use of neuraminidase inhibitors to combat pandemic influenza. J Antimicrob Chemother. 2006, 58: 911-915. 10.1093\/jac\/dkl376.","journal-title":"J Antimicrob Chemother"},{"key":"773_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/bsp.2006.4.366","volume":"4","author":"TV Inglesby","year":"2006","unstructured":"Inglesby TV, Nuzzo JB, O'Toole T, Henderson DA: Disease mitigation measures in the control of pandemic influenza. Biosecur Bioterr. 2006, 4: 1-10. 10.1089\/bsp.2006.4.1.","journal-title":"Biosecur Bioterr"},{"key":"773_CR12","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1098\/rspb.2007.0422","volume":"274","author":"ME Alexander","year":"2007","unstructured":"Alexander ME, Bowman CS, Feng Z, Gardam M, Moghadas SM, R\u00f6st G, Wu J, Yan P: Emergence of drug-resistance: implications for antiviral control of pandemic influenza. Proc R Soc B. 2007, 274: 1675-1684. 10.1098\/rspb.2007.0422.","journal-title":"Proc R Soc B"},{"key":"773_CR13","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1056\/NEJMoa054512","volume":"353","author":"MD de Jong","year":"2005","unstructured":"de Jong MD, Thanh TT, Khanh TH, Hien VM, Smith GJG, Chau NV, Cam BV, Qui PT, Ha DQ, Guan Y, Peiris JSM, Hien TT, Farrar J: Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med. 2005, 353: 2667-2672. 10.1056\/NEJMoa054512.","journal-title":"N Engl J Med"},{"key":"773_CR14","doi-asserted-by":"publisher","first-page":"e240","DOI":"10.1371\/journal.pcbi.0030240","volume":"3","author":"A Handel","year":"2007","unstructured":"Handel A, Longini IM, Antia R: Neuraminidase inhibitor resistance in influenza: assessing the danger of its generation and spread. PLoS Comput Biol. 2007, 3: e240-10.1371\/journal.pcbi.0030240.","journal-title":"PLoS Comput Biol"},{"key":"773_CR15","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(04)16934-1","volume":"364","author":"M Kiso","year":"2004","unstructured":"Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K, Hayden FG, Sugaya N, Kawaoka Y: Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet. 2004, 364: 759-765. 10.1016\/S0140-6736(04)16934-1.","journal-title":"Lancet"},{"key":"773_CR16","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1056\/NEJMp058291","volume":"353","author":"A Moscona","year":"2005","unstructured":"Moscona A: Oseltamivir resistance \u2013 disabling our influenza defenses. N Engl J Med. 2005, 353: 2633-2636. 10.1056\/NEJMp058291.","journal-title":"N Engl J Med"},{"key":"773_CR17","doi-asserted-by":"publisher","first-page":"4075","DOI":"10.1128\/AAC.49.10.4075-4084.2005","volume":"49","author":"HL Yen","year":"2005","unstructured":"Yen HL, Herlocher LM, Hoffmann E, Matrosovich MN, Monto AS, Webster RG, Govorkova EA: Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob Agents Chemother. 2005, 49: 4075-4084. 10.1128\/AAC.49.10.4075-4084.2005.","journal-title":"Antimicrob Agents Chemother"},{"key":"773_CR18","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1098\/rspb.2008.0016","volume":"275","author":"SM Moghadas","year":"2008","unstructured":"Moghadas SM: Management of drug-resistance in the population: influenza as a case study. Proc R Soc B. 2008, 275: 1163-1169. 10.1098\/rspb.2008.0016.","journal-title":"Proc R Soc B"},{"key":"773_CR19","doi-asserted-by":"publisher","first-page":"e1839","DOI":"10.1371\/journal.pone.0001839","volume":"3","author":"SM Moghadas","year":"2008","unstructured":"Moghadas SM, Bowman CS, R\u00f6st G, Wu J: Population-wide emergence of antiviral resistance during pandemic influenza. PLoS ONE. 2008, 3: e1839-10.1371\/journal.pone.0001839.","journal-title":"PLoS ONE"},{"key":"773_CR20","doi-asserted-by":"publisher","first-page":"6701","DOI":"10.1016\/j.vaccine.2006.05.067","volume":"24","author":"C Viboud","year":"2006","unstructured":"Viboud C, Tam T, Fleming D, Handel A, Miller MA, Simonsen L: Transmissibility and mortality impact of epidemic and pandemic influenza, with emphasis on the unusually deadly 1951 epidemic. Vaccine. 2006, 24: 6701-6707. 10.1016\/j.vaccine.2006.05.067.","journal-title":"Vaccine"},{"key":"773_CR21","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1098\/rsif.2007.1152","volume":"5","author":"N Arinaminpathy","year":"2008","unstructured":"Arinaminpathy N, McLean AR: Antiviral treatment for the control of pandemic influenza: some logistical constraints. J R Soc Interface. 2008, 5: 545-553. 10.1098\/rsif.2007.1152.","journal-title":"J R Soc Interface"},{"key":"773_CR22","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1371\/journal.pcbi.0020137","volume":"2","author":"A Handel","year":"2006","unstructured":"Handel A, Regoes RR, Antia R: The role of compensatory mutations in the emergence of drug resistance. PLoS Comput Biol. 2006, 2: 1262-1270. 10.1371\/journal.pcbi.0020137.","journal-title":"PLoS Comput Biol"},{"key":"773_CR23","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S0166-3542(01)00215-7","volume":"54","author":"J Carr","year":"2002","unstructured":"Carr J, Ives J, Kelly L, Lambkin R, Oxford J, Mendel D, Tai L, Roberts N: Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. Antiviral Res. 2002, 54: 79-88. 10.1016\/S0166-3542(01)00215-7.","journal-title":"Antiviral Res"},{"key":"773_CR24","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0166-3542(01)00214-5","volume":"54","author":"ML Herlocher","year":"2002","unstructured":"Herlocher ML, Carr J, Ives J, Elias S, Truscon R, Roberts N, Monto AS: Influenza virus carrying an R292K mutation in the neuraminidase gene is an transmitted in ferrets. Antiviral Res. 2002, 54: 99-111. 10.1016\/S0166-3542(01)00214-5.","journal-title":"Antiviral Res"},{"key":"773_CR25","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1126\/science.1122947","volume":"312","author":"RR Regoes","year":"2006","unstructured":"Regoes RR, Bonhoeffer S: Emergence of drug-resistant influenza virus: population dynamical considerations. Science. 2006, 312: 389-391. 10.1126\/science.1122947.","journal-title":"Science"},{"key":"773_CR26","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1001\/jama.295.8.jed60009","volume":"295","author":"DM Weinstock","year":"2006","unstructured":"Weinstock DM, Zuccotti G: Adamantane Resistance in Influenza A. JAMA. 2006, 295: 934-936. 10.1001\/jama.295.8.jed60009.","journal-title":"JAMA"},{"key":"773_CR27","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1371\/journal.pmed.0040015","volume":"4","author":"M Lipsitch","year":"2007","unstructured":"Lipsitch M, Cohen T, Murray M, Levin BR: Antiviral resistance and the control of pandemic influenza. PLoS Med. 2007, 4: e15-10.1371\/journal.pmed.0040015.","journal-title":"PLoS Med"},{"key":"773_CR28","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3934\/mbe.2007.4.159","volume":"4","author":"J Arino","year":"2007","unstructured":"Arino J, Brauer F, Driessche van den P, Watmough J, Wu J: A final size relation for epidemic models. Math Biosci Eng. 2007, 4: 159-175.","journal-title":"Math Biosci Eng"},{"key":"773_CR29","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/nature03063","volume":"432","author":"CE Mills","year":"2004","unstructured":"Mills CE, Robins JM, Lipsitch M: Transmissibility of 1918 pandemic influenza. Nature. 2004, 432: 904-906. 10.1038\/nature03063.","journal-title":"Nature"},{"key":"773_CR30","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.3201\/eid1108.041156","volume":"11","author":"RD Balicer","year":"2005","unstructured":"Balicer RD, Huerta M, Davidovitch N, Grotto I: Cost-benefit of stockpiling drugs for influenza pandemic. Emerg Infect Dis. 2005, 11: 1280-1282.","journal-title":"Emerg Infect Dis"},{"key":"773_CR31","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3201\/eid1402.070478","volume":"14","author":"MR Siddiqui","year":"2008","unstructured":"Siddiqui MR, Edmunds WJ: Cost-effectiveness of antiviral stockpiling and near-patient testing for potential influenza pandemic. Emerg Infec Dis. 2008, 14: 267-274. 10.3201\/eid1402.070478.","journal-title":"Emerg Infec Dis"},{"key":"773_CR32","doi-asserted-by":"publisher","first-page":"e2362","DOI":"10.1371\/journal.pone.0002362","volume":"3","author":"JM McCaw","year":"2008","unstructured":"McCaw JM, Wood JG, McCaw CT, McVernon J: Impact of emerging antiviral drug resistance on influenza containment and spread: influence of subclinical infection and strategic use of a stockpile containing one or two drugs. PLoS ONE. 2008, 3: e2362-10.1371\/journal.pone.0002362.","journal-title":"PLoS ONE"},{"key":"773_CR33","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1093\/aje\/kwj362","volume":"165","author":"ME Halloran","year":"2007","unstructured":"Halloran ME, Hayden FG, Yang Y, Longini IM, Monto AS: Antiviral effects on influenza viral transmission and pathogenicity: observations from household-based trials. Am J Epidemiol. 2007, 165: 212-221. 10.1093\/aje\/kwj362.","journal-title":"Am J Epidemiol"},{"key":"773_CR34","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1098\/rsif.2007.1126","volume":"4","author":"F D\u00e9barre","year":"2007","unstructured":"D\u00e9barre F, Bonhoeffer S, Regoes RR: The effect of population structure on the emergence of drug-resistance during pandemic influenza. J R Soc Interface. 2007, 4: 893-906. 10.1098\/rsif.2007.1126.","journal-title":"J R Soc Interface"},{"key":"773_CR35","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1086\/515246","volume":"177","author":"NI Stilianakis","year":"1998","unstructured":"Stilianakis NI, Perelson AS, Hayden FG: Emergence of drug resistance during an influenza epidemic: insights from a mathematical model. J Infect Dis. 1998, 177: 863-873.","journal-title":"J Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-9-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2334-9-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-9-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-9-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T07:52:39Z","timestamp":1630482759000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/1471-2334-9-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,22]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["773"],"URL":"https:\/\/doi.org\/10.1186\/1471-2334-9-8","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,22]]},"assertion":[{"value":"5 August 2008","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2009","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2009","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"8"}}